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Primary biliary cirrhosis is a frequent indication for 
liver transplantation. The purpose of this report is 
to present our experience with liver transplantation 
for primary biliary cirrhosis. Attention is given to 
the causes of hepatic dysfunction seen in allografts. 
In addition, we review the postoperative problems 
encountered and the quality of life at time of last 
follow-up in patients with transplants for primary 
biliary cirrhosis. A total of 97 orthotopic liver 
transplant procedures were performed in 76 pa-
tients with advanced primary biliary cirrhosis at 
the University of Pittsburgh from March 1980 
through September 1985. The transplant operation 
was relatively easy to perform. The most common 
technical complications experienced were fragmen-
tation and intramural dissection of the recipient 
hepatic artery, which required an arterial graft in 
20% of the cases. Most of the postoperative mortal-
ity occurred in the first 6 mo after transplantation, 
with an essentially flat actuarial life survival curve 
from that time point to a projected 5-yr survival of 
66%. Common causes of death included rejection 
and primary graft nonfunction. Thirteen of the 76 
patients had some hepatic dysfunction at the time of 
the last follow-up, although none were jaundiced. 
Recurrence of primary biliary cirrhosis could not be 
demonstrated in any of the patients. Antimitochon-
drial antibody was detected in the serum of almost 
all of the patients studied postoperatively for it. 
Most important, almost all of the 52 surviving 
patients have been rehabilitated socially and voca-
tionally. 
Primary biliary cirrhosis (PBC) , or chronic non-
suppurative destructive cholangitis, is a slowly 
progressive disease of unknown etiology that fre-
quently has associations with other autoimmune 
diseases (1-3). Primary biliary cirrhosis chiefly affects 
middle-aged women. The diagnosis is established 
using a combination of clinical findings, particularly 
chronic cholestasis, the presence of antimitochon-
drial antibodies (AMAsJ, increased immunoglobulin 
M levels, and liver biopsy findings of a chronic 
inflammatory process, particularly lymphocytic in-
filtration within portal tracts and interlobular bile 
ducts (when detected earlyJ or an absolute paucity of 
bile ducts in the cirrhotic stage of the disease (4,5J. 
Hepatic failure or variceal hemorrhage, or both, are 
common terminal events (6J. 
In the past, medical treatment has consisted of the 
management of symptoms and the prevention, early 
recognition, and treatment of systemic complica-
tions. More recently, orthotopic liver transplantation 
(OLT) has been offered as a therapeutic modality to 
patients with advanced disease (7). However, Neu-
berger et a1. (8) have reported the recurrence of PBC 
in 3 of their first 11 liver transplant recipients 
operated on for PBC. This report somewhat quieted 
the initial enthusiastic acceptance of liver transplan-
tation for this particular indication. Herein we report 
the results of hepatic replacement in 76 patients 
with PBC who were treated between March 1980 and 
September 1985 at the University of Pittsburgh using 
cyclosporine and prednisone as the immunosup-
pressive agents. In cases that manifested postoper-
ative graft dysfunction, attempts were made to de-
Abbreviations used in this paper: AMA, antimitochondrial 
antibody; OLT. orthotopic liver transplantation; PBC, primary 
biliary cirrhosis. 
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termine whether or not recurrence of PBC was 
responsible. 
Materials and Methods 
The records of 450 liver recipients treated between 
March 1980 and September 1985 at the University of 
Colorado (until February 1981) and the University of 
Pittsburgh (since February 1981) were reviewed. Based on 
preoperative evaluation and pathologic examination of the 
resected livers, 76 recipients had PBC as the indication for 
liver transplantation. The immunosuppression used in all 
cases was cyclosporine and prednisone (7) to which 
antilymphocyte globulin or, more recently, the monoclo-
nal antibody OKT3 (Orthoclone, ORTHO, Pharmaceutical 
Corporation, Raritan, N.J.) had been added for short inter-
vals to treat rejection episodes (9). In a few patients with 
smoldering rejection, low doses of azathioprine were 
added to the standard combination of cyclosporine and 
prednisone. 
Before OLT, signs and symptoms of PBC had been 
present for more than 5 yr in 58% of the cases in this series 
(Table 1). At the time of initial evaluation, their ages 
ranged from 31 to 68 yr. The female/male ratio was -10: 1. 
The most common symptoms and signs were jaundice, 
pruritus, gastrointestinal bleeding, and fatigue. Hepato-
splenomegaly, ascites, and bone disease were also com-
mon (Table 1). 
Operative Procedures and Findings 
Liver transplantation was performed using a tech-
nique described previously (10), including venous bypass 
for the last 61 recipients (11). Most of the excised livers 
were considerably larger than normal. Although hilar 
lymphadenopathy and portal hypertension were common 
findings at surgery, the hepatectomies were easy to per-
form, particularly when there had been no previous surgi-
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cal procedures performed in the right upper quadrant of 
the recipient. In 2 patients the hepatectomy was compli-
cated by the presence of a surgically created portal-
systemic shunt performed 3 and 4 yr before OLT. 
Special problems with the rearterialization phases of the 
OLT procedure were common and were caused by the 
friability of the recipient's hepatic arteries. which had a 
tendency for intimal dissection at the site of ligation of 
arterial branches or where vascular clamps were applied. 
When dissection was recognized (20% of patients). an 
interposition graft. using the donor iliac artery (12). was 
placed proximal to the infrarenal recipient aorta and was 
tunneled through the retroperitoneum to the graft hilar 
area. where it was anastomosed to the graft arterial supply 
(12). 
The most common biliary reconstruction used was a 
duct-to-duct anastomosis (86% of patients) over aT-tube 
stent. The only commonly used alternative method was a 
choledochojejunostomy to a Roux-en-Y limb (13% of pa-
tients) (7). 
Laboratory Data 
Total bilirubin. alanine transaminase. alkaline 
phosphatase, and y-glutamyl transferase were assayed 
before transplantation. at multiple times after transplanta-
tion, and at the time of last follow-up in all surviving 
recipients (November 1986). After patients were dis-
charged from the hospital. many different laboratories 
performed these tests and considered them abnormal only 
if the result was >1.5 mgldl for total bilirubin. 37 lUlL for 
alanine transaminase. 100 lUlL for alkaline phosphatase, 
and 44 lUlL for y-glutamyl transferase. 
The preoperative mean total bilirubin level was 20.1 
mgldl (range 1.5-51.0). The single patient with a bilirubin 
of 1.5 mgldl at the time of OLT was bedridden because of 
numerous fractures and had had two episodes of variceal 
gastroesophageal hemorrhage. The mean alkaline phos-
Table 1. Characteristics of 76 Liver Transplant Recipients for Primary Biliary Cirrhosis 
Time from onset of 
symptoms to 
transplantation Clinical features 
Age and sex distribution No. of No. of No. of 
Age Time patients patients patients 
(yr) Male Female (yr) (%) Symptoms (%) Signs (%) 
30-39 1 14 1 3 (4.0) Pruritus 50 (65.8) Jaundice 75 (97) 
40-49 2 41 2 4 (5.3) Fatigue 31 (40.8) Ascites 55 (72) 
50-59 2 13 3 8 (10.7) Abdominal pain 17 (23) Gastrointestinal 55 (72) 
hemorrhage 
2:60 2 1 4 8 (10.7) 
Total 7 69 5 9 (12.0) Encephalopathy 25 (33) Hepatomegaly 52 (6.9) 6 9 (12.0) Splenomegaly 39 (52) 
7 9 (11.8) Xanthomas 14 (18.4) 
8 5 (6.6) 
9 8 (10.7) 
10 7 (9.3) 
>10 6 (8.0) 
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Table 2. Assessment of Histologic Findings in Primary 
Biliary Cirrhosis Compared With Acute and 
Chronic Rejection 
Endstage PBC 
Granuloma + 
Lymphoid follicles + + 
Portal and central vein 
infiltration 
Bile duct damage + + + 
Bile duct loss + + + 
Chronic vascular + 
lesionsU 
Cholestasis 
Tissue copper 
deposition 
Cirrhosis b 
Marginal duct 
proliferation 
Peripheral 
+ +/Peripheral 
++ 
++ 
Acute Chronic 
rejection rejection 
+/- + 
++ + 
+ +++ 
+/- +++ 
+++ 
Central Central 
PBC, primarv biliary cirrhosis. a Subintimal foam cells in artenal 
and portal veins. fibrointimal hyperplasia. intimal sclerosis. and 
rupture and duplication of internal elastic lamina of large arteries 
are seen in chronic rejection. Mild atherosclerotic changes mav be 
seen in large hilar arteries of PBC livers. b Portal-to-centrallinkage 
with regenerative parenchymal nodules. C :\'ormally seen only 
after treatment of severe acute rejection. 
phatase level before transplantation was 695 IUIL (range 
43-2640). The mean alanine transaminase was 163 IU/L 
with a range from 12 to 1011, and the mean y-glutamyl 
transferase was 374 IU/L (range 20-2115). 
Preoperative AMA titers were compared to those ob-
tained postoperatively and at last follow-up as of Novem-
ber 1986 for all surviving patients. 
Pathologic Studies 
Representative sections of the liver were obtained 
and examined from both lobes of the resected liver. Ac-
cording to protocol. three hilar sections containing major 
blood vessels. nerve trunks, and bile ducts were obtained 
and examined (13). All sections were stained with hema-
toxylin and eosin. trichrome. orcein. and rhodanine and 
were examined by light microscopy. The orcein and 
rhodanine stains were used for the detection of copper-
binding protein and copper within the tissue. respectively. 
Histologic staging of the native liver (stages I-IV) was 
determined using established criteria (5,14). 
A similar protocol was used to histologically assess all 
failed allografts if either autopsy or retransplantation oc-
curred. Posttransplant biopsy specimens from dysfunc-
tional allografts, particularly those obtained beyond 2 mo 
postoperatively, were evaluated similarly. All histologic 
specimens were evaluated by a staff pathologist (A.J.D.) for 
the following: (a) presence of cirrhosis, (b) marginal 
ductular proliferation. (c) granulomas. (d) portal or septal 
lymphoid nodules. (e) location of cholestasis (if present). 
(f) portal or hepatic venous subendothelial infiltration (or 
both). (g) mononuclear inflammatory cell damage of the 
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bile ducts and ductular loss. (h) chronic arterial or venous 
lesions (or both) (15), and (i) the presence and location of 
tissue copper and copper-binding protein accumulation. 
Rejection was considered to be present if the patient 
developed postoperative abnormalities in any of the he-
patic injury tests performed. whether or not symptoms 
such as fever. anorexia. and abdominal pain occurred. In 
most cases. liver biopsy specimens were obtained to either 
confirm or refute the clinical impression of rejection. 
Clinical pathologic correlations were attempted systemat-
ically. but for differentiating acute or chronic rejection 
from recurrent PBC. the morphologic criteria summarized 
in Table 2 were used. 
Data Analysis 
All data are presented as mean values and range. 
Patient survival was calculated by the life table method 
(MOP statistical software. Los Angeles. Calif.). The ,i-test 
was used to test differences between proportions and the 
significance of associations. A probability value <0.05 was 
considered to be significant. 
Results 
Survival 
Fifty-two (68%) of the 76 recipients are alive 
at follow-ups of 1-6.5 yr. During the 1980-1985 
period of case accrual. the survival of patients with 
PBC was arithmetically better than that of adult 
recipients with all other indications for the proce-
dure (Figure 1). This difference was due largely to 
inclusion in the latter curve of many recipients with 
diseases such as hepatitis B-positive cirrhosis and 
hepatic malignancy, which have a high incidence of 
lethal recurrence within 1-3 yr. For patients with 
PBC. calculated survival curves appear to be flat after 
the first full year of survival. with an actuarial 5-yr 
survival of 66% (Figure 1). 
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Figure 1. Actuarial survival of adult liver transplant recipients 
using cyclosporine. The numbers in our graph identify 
the number of patients alive at each time point. There is 
no statistical difference between the two groups in 
survival. 
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Patient survival for the PBe group would have 
been considerably less favorable without the fre-
quent use of retransplantation. In 19 of the 76 recip-
ients (25%) with PBe, retransplantation was per-
formed within a few days to almost 3 yr after the 
initial graft. In 2 of the cases, three successive 
transplant procedures were attempted. It is impor-
tant to note that 9 of the 19 patients (47%) who 
required retransplantation are included among the 
52 current survivors. This retransplantation rate is 
somewhat greater than that in all other groups, but 
was possible because of the better overall general 
condition of PBe patients before initial transplanta-
tion as compared with those transplanted for other 
indications. Moreover, the level of functioning of 
other critical (nonhepatic) organs such as the lungs 
and kidney. and the presence or absence of infec-
tion-not the severity of the initial or even subse-
quent hepatic dysfunction-determine whether or 
not retransplantation is possible. These other factors 
are less of a problem in patients transplanted for PBe 
than they are for those transplanted for other indi-
cations. 
Table 3 shows the proportion of patients alive at 
the time of last follow-up segregated according to 
duration of survival and six clinical parameters 
frequently used to categorize patients. No difference 
in either short- or long-term survival was seen be-
tween groups of PBe patients based upon age, total 
Table 3. Proportion of Patients ,-\1ive at Time of Last 
Follow-up 
i\ge ('If) 
<50 
250 
Bilirubin (total) (mg/dl) 
<10 
2'10 but <15 
2:15 
Albumin (g/dl) 
<3 
2:3 
Ascites 
Yes 
:\0 
Previous gastrointestinal 
bleeding 
Yes 
0io 
Clinical encephalopathy 
Yes 
:--Jo 
Duration of follow-up 
<6 mo 6 ma-l vr 1-5 yr >5 yr 
fn = 36) (n = 14) (n = 24) (n = 2) 
40 
42 
29 
86 
58 
50 
41 
36 
55 
36 
55 
15 
57 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
75 
100 
100 
100 
100 
100 
95 100 
100 100 
100 100 
100 100 
80 
100 100 
80 
100 100 
94 
All values are percentages. 
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Table 4. Causes of Death in Patients With Primarv 
Biliary Cirrhosis After Liver Transplanta'tion 
Rejection 
Graft nonfunction 
Hepatic artery thrombosis 
Bacterial pneumonia 
Pneumocystis carinii pneumonitis 
Intraoperative 
OtherG 
010. days 
«90. early) 
9 
3 
1 
2 
2 
2 
No. davs 
(2:90. late) 
2 
a One patient died of an intraoperative myocardial infarction 
during a reduction of a hip fracture. another died of colchicine-
induced hepatic necrosis. and a third died of complications of 
vagotomy and near-total gastrectomy for peptic ulceration and 
hemorrhage. 
bilirubin or albumin levels, the presence or absence 
of ascites. or a history of gastrointestinal bleeding. 
However. the survival of patients who had clinically 
evident hepatic encephalopathy before OL Twas 
reduced ('56%) compared with that of those without 
encephalopathy (78%) [y = 4.186; p < 0.05). 
Causes for Mortality 
The 24 deaths that occurred in this series are 
summarized in Table 4. Two patients died during 
the OLT operation as a result of technical difficulties. 
Postoperatively. rejection was the single most pre-
dominant cause of death, either because retransplan-
tation was not possible (3 cases) or unsuccessful (7 
cases). Primary graft nonfunction, although uncom-
mon, was associated with a 100% mortality. 
Table 5. Postoperative Complications Requiring 
Additional Operations 
\10. Percentage 
\Vound infection 10 13.3 
. Biliary fistula 8 10.6 
Gastrointestinal hemorrhage 5 6.6 
Hemoperitoneum 5 6.6 
Hepatic arterial thrombosis 3 4.0 
Aortic aneurysm 2 2.6 
Portal vein rupture 2 2.6 
Pyloric stenosis 2 2.6 
Duodenal fistula 1.3 
Intestinal perforation 1.3 
Portal vein thrombosis 1.3 
Common bile duct stricture 1.3 
lntraabdominal abscess 1.3 
Total 42 
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Table 6. Performance Status Determined Preoperatively 
and Postoperatively at the Time of Last 
Follow-up 
Classification Preoperative Postoperative 
In coma in lCU 0 
In an lCU 4 0 
In hospital 11 1 
At home with care 38 2 
At home with self-care 19 28 
Working part time 2 4 
Working full time 1 i7 
Total 76 52 
ICU. intensive care unit. 
Morbidity and Rehabilitation 
Excluding retransplantation. the postopera-
tive complications experienced by patients trans-
planted for PBC and requiring surgical intervention 
are listed in Table 5. Wound infection was the most 
common problem followed closely by the need for 
biliary tract revision. 
Seventeen of the 52 surviving patients are cur-
rently working full time, 4 are working part time. 2 
are partially disabled, and 1 is in the hospital with a 
seizure disorder (Table 6). 
When the performance status of patients before 
and after OLT (at the time of last follow-up) are 
compared. the proportion of those successfully func-
tioning postoperatively (94%) (defined as being ei-
ther at home caring for themselves or working full or 
part time) increased significantly (preoperatively 
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29%; r = 43.853; P < 0.001). Moreover, when the 
proportion of patients who were not hospitalized but 
required some form of care is examined, it can be 
seen that only 4% of the patients required postoper-
ative care at home compared with 50% preopera-
tively (r = 43.853; P < 0.001). Consistent with these 
data are the data concerning the percentage of pa-
tients with either bone pain or fractures during the 
preoperative period (40%), early postoperative pe-
riod (30%), and late postoperative period (13%) (r = 
7.250; P < 0.05). It should be noted. however. that 
several patients required prolonged (3-6 mo) post-
operative in-hospital rehabilitation because of previ-
ous bone disease before their functional status im-
proved postoperatively. 
Liver Function 
Thirteen of the 52 surviving patients continue 
to have some abnormalities of liver function (Table 
7). However. the hepatic dysfunction is minor and 
no patients are jaundiced. 
Antimitochondrial Antibody Titers 
Sixty-four of the 76 recipients were tested for 
the presence of AMA before transplantation. Sixty-
three (98%) of these patients were found to be 
positive for this antibody; in 40 the initial titer was 
>1:80. 
Although complete AMA titer data could not be 
obtained for all ·of the survivors. in 43 of 45 cases 
evaluated AMAs continued to be detected through-
out at the same level or were found to decline 
Table 7. Biochemical and Serologic Measures of Hepatic Dysfunction at Last Follow-up in the Patients Studied 
Total 
Date of bilirubin ALT GGT AP AMA Date of 
OT OLT (mgldl) (IU) (IU) (IU) Preoperative Postoperative Diagnosis biopsy 
230 4-82 0.6 34 112 562 1:40 1:160 No biopsy 
280 2-83 1.2 107 511 473 1:1000 1:80 Mild chronic rejection 9-83 
319 9-83 0.7 16 95 165 1:100 Neg No biopsy 
350 1-84 0.5 96 309 114 1:100 1:160 Reticuloendothelial and parenchymal 12-85 
cell iron deposition 
359 1-84 1.3 41 87 66 1:60 Neg No biopsy 
361 2-84 0.8 125 142 198 1:40 1:40 No biopsy 
497 2-85 0.6 59 164 133 1:1000 1:100 Chronic rejection: portal fibrosis 4-85 
507 3-85 0.3 107 58 201 1:10 1:10 Acute rejection 11-86 
519 4-85 1.1 86 1510 622 1:160 Neg Chronic rejection; disappearing ducts 7-85 
550 6-85 1.3 423 232 140 Fatty deposition 4-86 
585 8-85 0.7 42 225 88 1:300 1:50 Mild cholestasis 8-85 
588 8-85 0.7 29 71 163 1:200 1:40 Acute rejection 9-85 
596 8-85 0.8 31 96 270 1:10 Neg No biopsy 
Upper normals 1.5 37 44 100 <1:10 
ALT. alanine transaminase; AP. alkaline phosphatase; AMA. antimitochondrial antibody; GGT. y-glutamyl transferase; OLT. orthotopic 
liver transplantation; ~qK the number given to liver transplant recipients. 
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Figure 2. Antimitochondrial antibody titers before and after he-
patic transplantation in PBC patients. The majority of 
the patients have had a decline in the AMA titers. 
relative to the initial preoperative value (Figure 2). 
No relationship between the height of the initial or 
follow-up AMA titer and the quality of postoperative 
liver function is evident. Six of the recipients with 
entirely normal posttransplantation liver function 
continue to have positive AMA titers as long as 1-4.5 
yr after transplantation. Because of the lack of a 
clinical indication. liver biopsies have not been 
performed in these 6 individuals. 
Special attention has been paid to the 13 recipi-
ents with abnormal liver function. The AMA titer in 
10 of these patients has either decreased or remained 
stable at the pretransplant level. In two other pa-
tients. the titer has increased. but the bilirubin level 
has remained normal and both transaminase and 
alkaline phosphatase activities have not become 
abnormal. A liver biopsy specimen obtained from 1 
of these 2 patients showed increased iron deposi-
tion. 
Pathologic Observation 
Native livers. Ninety percent of the native 
Ii vers were stage IV. 9% were stage III. and 1 % was 
between stage II and III at the time of hepatectomy. 
Thus. the vast majority of the specimens demon-
strated far advanced disease with either macronod-
ular cirrhosis or advanced fibrosis with a paucity of 
bile ductules in the fibrous septa (Figures 3A and 
3B). Other conspicuous features included the pres-
ence of portal granulomata and lymphoid follicles, 
marked paraseptal cholestasis with an accumulation 
of tissue copper and copper-binding protein, an 
irregular margin between the fibrous septa and re-
generative nodules, and the occasional findings of 
Mallory'S hyaline. 
Liver homografts. Grafts failing as a result of 
chronic rejection were easily separable from native 
GASTROENTEROLOGY Vol. 94. No.5, Part 1 
livers by light microscopy (Figures 3 and 4). Chronic 
arterial and venous lesions including subintimal 
foam cells and myointimal hyperplasia were present 
only in failed grafts and were never found in native 
livers (Figure 3C). In failed homografts, fibrosis was 
seen in portal and central areas. but true cirrhosis 
was never evident (Figure 3D). In addition to a 
relative paucity of inflammatory cells, it was found 
that granulomas. marginal cholangiolar prolifera-
tion, and deposition of tissue copper were absent or 
uncommon in failed grafts but common in native 
organs. The cholestasis associated with chronic re-
jection was predominantly centrilobular, whereas in 
the native liver it occurred predominantly in a 
paraseptal (paraportal) location. A common feature 
of both resected native organs and homografts was 
the presence of a nonsuppurative destructive chol-
angitis, which in grafts was thought to be a manifes-
tation of rejection rather than recurrent disease (16). 
Biopsy specimens showing acute rejection differed 
from those of endstage PBC, principally by the 
presence of a subintimal accumulation of mononu-
clear cells in the portal and hepatic veins present in 
rejecting organs but not in native organs. Both acute 
rejection and PBC are characterized by a mononu-
clear portal inflammatory infiltrate with destructive 
duct lesions; however, the inflammatory infiltrate in 
PBC often extends well into the adjacent hepatic 
lobule, whereas this is quite unusual in rejection 
(Figures 3B and 4). 
Discussion 
Primary biliary cirrhosis has become the sec-
ond most common indication for OLT in adults, 
being exceeded only by posthepatic cirrhosis as a 
reason for OLT. The decision about the proper tim-
ing of OLT for patients with PBC has been made 
somewhat less difficult than it is for other indica-
tions as a result of the prognostic indices that have 
been developed using common clinical and patho-
logic criteria available at most centers (17,18). Virtu-
ally all of the patients in this series met criteria for 
advanced disease that predict that without trans-
plantation death is likely within ::0::1 yr (6,18). In the 
future, perhaps many doctors will not allow patients 
to become mortally ill before performing OL T, as 
was the case in this series (Tables 1 and 6). More-
over, it is unlikely that as many patients will have 
previous upper abdominal surgery such as portal 
systemic shunts performed before transplantation, as 
was the case in several of our patients. 
The liver transplant operation in patients with 
PBC is easier to perform than it is for most other 
adult liver diseases. especially in the absence of 
previous upper abdominal surgical procedures. The 
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Figure 4. Lymphocytic bile duct damage is observed in both PBC and allograft rejection . However. whereas rejection preferentially 
involves small ducts and ductules (A. H&E. magnification X400), intermediate-sized ducts are targeted in early PBC in 
association with granulomas (B. H&E. magnification x 150) and germinal centers. features not seen in rejection . 
enlarged liver, the usual absence of major collaterals 
in the hepatic suspensory ligaments and bare areas, 
the usual normal consistency and configuration of 
both the suprahepatic inferior vena cava and the 
portal vein, and the presence of a normal recipient 
common duct are features present in patients with 
PEe that make the procedure easier to perform. With 
the use of the venous bypass, liver replacement in 
patients with PEe can be accomplished with very 
little blood loss and with little, if any, physiologic 
derangement during the operative procedure (10,11). 
A technical problem unique to transplant recipi-
. ents with PEe is the fragility of the recipient hepatic 
arteries. The media and subintima can be separated 
from the rest of the artery with the slightest trauma 
including the application of vascular clamps in 
preparation for an anastomosis and ligation of the 
gastroduodenal artery or other branches. Intramural 
dissection of the damaged vessel proximal to or 
beyond the level of the left gastric and splenic 
arterial branches can occur. If the diagnosis of a 
dissection is made, it is necessary to use an iliac graft 
to prevent subsequent thrombosis (12). Intimal dis-
section occurred in 20% of the cases in the present 
May 1988 
series. The acceptance of a suboptimal arterial sup-
ply in cases with dissection is often a prelude to 
tragedy (19). 
Because of the greatly improved quality of life 
experienced by surviving patients. the use of OL T in 
PBG has become increasingly attractive. Evaluation 
of the current experience with OL T for this indica-
tion demonstrates that survival and particularly the 
quality of life of patients is enhanced with OLT 
compared with standard medical therapy (Tables 3 
and 6). Most of the mortality experienced after OLT 
occurs in the first 6 rna with 22 of the 24 deaths 
occurring during the admission for transplantation. 
Based on the results reported herein. it appears that 
transplantation for individuals with advanced PBG 
is efficacious. Future improvements in the preoper-
ative selection of patients. surgical technique. and 
postoperative management. as well as more selective 
or limited use of immunosuppression. should re-
duce the early surgical mortality and enhance fur-
ther the acceptability of OL T as a treatment for 
patients with advanced PBG (9). 
The only disquieting observation relevant to the 
application of OLT for patients with PBG has come 
from Neuberger et al. (8). who reported clinical and 
histopathologic evidence for recurrent PBG in 3 of 11 
patients who underwent liver replacement for PBG 
using azathioprine and prednisone. The absence of 
recurrence in the present series with follow-ups of 
1-6.5 yr, however. is encouraging. The many his-
tologic similarities between PBG and rejection. as 
well as graft-versus-host liver disease, may make it 
difficult to separate disease recurrence from rejec-
tion. Our experience suggests that truly recurrent 
disease is quite unusual. Similar results were re-
ported by Haagsma et al. (20), who found no evi-
dence of recurrence of PBG in 9 liver transplant 
recipients followed for at least 1 yr. Attention to the 
fine details of the type of inflammatory cells found 
mostly in the portal areas, the degree to which these 
cells infiltrate the surrounding parenchyma. and the 
presence or absence of subintimal foamy macro-
phages and true cirrhosis (regenerative nodules and 
fibrosis) apparently make it possible to distinguish 
between these two entities. 
It is conceivable that the superior immunosup-
pression achieved with cyclosporine combined with 
steroids aborts the underlying autoimmune manifes-
tations of PBG while also controlling the rejection 
process. The AMA test, which has been considered a 
relatively specific diagnostic indicator of PBG. does 
not become negative after transplantation (20,21). 
Moreover, although the AMA titers tend to decline 
with time after transplantation (Figure 2), such 
changes in individual cases have been unpredict-
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able. It may be that future studies of specific 
subtypes of AMA in posttransplant patients will 
provide either more information or new insights into 
the pathogenesis of this disease. It is conceivable 
that if recurrence of PBG should occur it will be a 
slow and gradual event. If recurrence were found to 
be the case. the process would develop at such a 
slow pace that transplantation for patients with 
advanced PBG would still be a reasonable course of 
action. 
Much remains to be learned about both PBG and 
the process of hepatic rejection. We hope that as 
experience with both increases. the knowledge avail-
able about the two conditions will increase. and that 
newer and better therapies will be developed. 
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